H. Lundbeck

Lundbeck reported strong financial results for 2024, with revenue of DKK 22B ($3.2B), representing 14% growth at constant exchange rates. Adjusted EBITDA increased by 20% to DKK 6,347M with strategic brands revenue reaching DKK 16.3B. Recent regulatory advancements include Fast Track Designation for amlenetug for Multiple System Atrophy from the FDA and Orphan Drug Designation in Japan, highlighting the company's continued focus on addressing unmet needs in neurological disorders.